Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2025)

Evommune (EVMN) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $326000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 9.44% to $326000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $686000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1.4 million for FY2025, 7.93% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $326000.0 at Evommune, down from $360000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $360000.0 in Q4 2024, with the low at $326000.0 in Q4 2025.